LOGIN
Transforaminal vs Posterior Lumbar Interbody Fusion For Symptomatic Single-Level Spondylolisthesis
November 2025
Transforaminal vs Posterior Lumbar Interbody Fusion For Symptomatic Single-Level Spondylolisthesis
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1
Transforaminal versus posterior lumbar interbody fusion for symptomatic single-level spondylolisthesis (LIFT): a multicentre controlled, patient blinded, randomised non-inferiority trial.
Lancet Reg Health Eur . 2024 Jun 19:43:100964.Synopsis
One hundred fifty eight patients with symptomatic single-level (degenerative, isthmic, or iatrogenic) spondylolisthesis were randomized 1:1 to TLIF (n=78) or PLIF (n=80). The primary outcome was change in ODI from baseline to 12 months. Secondary outcomes included QALYs (EQ-5D-5L, SF-36), back/leg pain (NRS), anxiety/depression (HADS), peri-operative blood loss, operative time, length of stay, and...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.